

SCCL RETREAT, November 13&14, 2023

Program

Day 1 – Nov 13

Welcome & introduction, 9h00, David Gfeller

Session 1: 9h15 – 10h30: Quatre Cathédrales, Lausanne-Genève-Fribourg-Bern

Chair: Mikael Pittet

- 9h15-9h30: Bolli Evangelia, Mikael Pittet group, UNIGE. *Deciphering tumor-promoting mechanisms mediated by neutrophils in vivo*
- 9h30-9h45: Derré Laurent, Denise Nardelli-Haeffliger group, CHUV. *Intravesical Ty21a treatment of non-muscle-invasive bladder cancer patients*
- 9h45-10h00: Sun Mengzhu, Stephanie Hugues group, UNIGE. *Lymphatic-derived 25-hydroxycholesterol promotes immunity in melanoma by inhibiting PPAR-gamma in tumor associated macrophages and monocytes*
- 10h00-10h15: Ibrahim Ghada, Manuela Eicher group, CHUV. *The Patient Lab and its role in PPIE implementation*
- 10h15-10h30: Birsén Rudy, Jérôme Tamburini group, UNIGE. *C/EBP α Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress-Induced Ferroptosis in FLT3-Mutant Leukemia*

Coffee break: 10h30 – 11h00

Session 2: 11h00 – 12h15: Musée olympique, Lausanne

Chair: Patrycja Nowak

- 11h00-11h15: Cenerenti Mara, Jandus group, UNIGE. *Tumor-specific CD4 T cells: the unexpected human cancer killers*
- 11h15-11h30: Sukarie Rania, Lana Kandalaf group, UNIL. *Development of a novel B cell-based vaccine against solid cancers*
- 11h30-11h45: Rath Jan, Caroline Arber group, CHUV. *Designed tumor microenvironment responsive biosensors enhance chimeric antigen receptor T cell therapy for cancer*
- 11h45-12h00: Du BoisValentine, Intidhar Labidi-Galy group, HUG. *Nab-PIPAC: a phase IB study of intraperitoneal cisplatin and nab-paclitaxel administered by PIPAC for peritoneal carcinomatosis: preliminary translational results*
- 12h00-12h15: Andreatta Massimo, Santiago Carmona group, UNIL. *From single cells to patient stratification*

Lunch: 12h15 – 13h30

Poster Session: 12h15 – 15h00

Session 3: 15h00 – 16h15: Palais des Nations, Genève

Chair: Freddy Radtke

- 15h00-15h15: Schlaeppli Anjalie, Jessica Dessimoz group, EPFL. *Implementing imaging-based spatial transcriptomics at EPFL*
- 15h15-15h30: Koval Alexey, Vladimir Katanaev group, UNIGE. *Targeting the heart of FZD receptors in tumours for highly selective 2nd generation targeting of Wnt signalling*
- 15h30-15h45: Su Zhouxing, Gaide Olivier group, CHUV. *Study of the effects of 5G waves on human skin*
- 15h45-16h00: Sifis Alexandros, Jean Perentes group, CHUV. *Hyperthermic intrathoracic chemotherapy to boost response to checkpoint blockade immunotherapy*
- 16h00-16h15: Álvarez-Prado Ángel, Johanna Joyce group, UNIL. *Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors*

Break: 16h15 – 16h45

Session 4: 16h45 – 18h00: Palais Fédéral, Bern

Chair: Susan Gasser

- 16h45-17h00: Pejowski David, Leonardo Scapozza group, UNIGE. *Development of Improved Adenosine Pathway-Targeting Cancer Immunotherapies; an Allosteric Small Molecule Approach*
- 17h00-17h15: Thouenon Romane, Dr. Grégory Verdeil group, UNIL. *An IRF4 mutation affecting the interferon association domain is associated to an autosomal dominant primary immunodeficiency*
- 17h15-17h30: Walker Cédric, Sven Rottenberg group, UNIBE. *Computationally-derived stromal phenotypes, along with tumor-infiltrating lymphocytes, are associated with progression-free survival in high-grade serous ovarian carcinoma digital pathology slides*
- 17h30-18h00: Special guest - Haruhiko Koseki, RIKEN. *Regeneration of natural killer T (NKT) cells: application of iPSC technology for NKT cell-targeted tumor immunotherapy*

Apero dinatoire: 18h00 – 20h00

Day 2 – Nov 14

Session 5: 9h00 – 10h30: Basse-ville, Fribourg

Chair: Tatiana Petrova

- 9h00–9h15: Bruand Marine, Elisa Oricchio group, EPFL. *Cathepsin S Regulates Tertiary Lymphoid Structures Formation in Solid Tumors and Germinal Centers Development in B-cell Lymphoma*
- 9h15–9h30: Pétremand Rémy, Alexandre Harari group, CHUV. *Combinatorial Algorithms to Predict Clinically-Relevant TCRs for Personalized T-Cell Therapy*
- 9h30–9h45: Lecointre Morgane, Douglas Hanahan group, EPFL. *Pharmacological targeting of IL-1 signaling disrupts cancer-induced systemic immunosuppression and improves therapeutic vaccine response in HPV16-induced cancer*
- 9h45–10h00: Benboubker Valentin, Patrycja Nowak-Sliwinska group, UNIGE. *Leveraging Optimized Drug Combinations to Enhance Immunotherapy Efficacy in Colorectal Carcinoma*
- 10h00–10h15: Tardivon Delphine, Nathalie Rufer group, CHUV. *Specific TCR/CDR mutations positively or negatively modulate the functional efficacy of NY-ESO-1-redirected CD8 T cells in a mutually exclusive manner*
- 10h15–10h30: Javary Joaquim, Fredy Radtke group, EPFL. *SOX2 drives resistance to Notch inhibitors by repressing NOTCH transcription, inducing EMT and stemness in triple negative breast cancer*

Coffee break: 10h30 – 11h00

Poster session: 10h30 – 13h15

Lunch: 12h00 – 13h15

Session 6: 13h15 – 14h45: Jet d'eau, Genève

Chair: Olivier Michielin

- 13h15-13h30: Dupuychaffray Eloïse, Carole Bourquin group, UNIGE. *Obesity-derived estrogens modulate the efficacy of cancer immunotherapy in melanoma.*
- 13h30-13h45: Rota Ioanna, George Coukos group, UNIL. *Understanding the transcriptional, epigenetic and metabolic rewiring underpinning CD8 T-cell differentiation into powerful tumor-rejecting synthetic cells*
- 13h45-14h00: Simó-Riudalbas Laia, Didier Trono/Alexandre Reymond group, EPFL/UNIL. *POU5F1B is a human-restricted ROCK inhibitor-sensitive pro-metastatic factor that nucleates membrane nanodomains*
- 14h00-14h15: Arpa Enes Salih, David Gatfield group, UNIL. *Investigating the role of nonsense-mediated mRNA decay in hepatocellular carcinoma*
- 14h15-14h30: Hérault Léonard, David Gfeller group, UNIL. *Reconciling single-cell multiomics modalities using metacells*
- 14h30–14h45: Mansouri Nahal, Michele De Palma group, EPFL. *Basophil-mediated suppression of Tregs controls tumor growth*

Short break: 14h45 – 15h00

Keynote speaker: 15h00 – 15h45: Anna Obenauf, IMP Vienna. *Towards rational combination therapies: Understanding tumor evolution during therapy response and resistance.*

Chair: TBD

15h45: Best talk and best posters awards

Chair: Doug Hanahan

16h00: Closing Remarks: Intidhar Labidi-Galy